ES2133316T3 - Secuencias peptidicas especificas de las fases hepaticas de p. falciparum portadoras de epitopos capaces de estimular los linfocitos t. - Google Patents

Secuencias peptidicas especificas de las fases hepaticas de p. falciparum portadoras de epitopos capaces de estimular los linfocitos t.

Info

Publication number
ES2133316T3
ES2133316T3 ES92905897T ES92905897T ES2133316T3 ES 2133316 T3 ES2133316 T3 ES 2133316T3 ES 92905897 T ES92905897 T ES 92905897T ES 92905897 T ES92905897 T ES 92905897T ES 2133316 T3 ES2133316 T3 ES 2133316T3
Authority
ES
Spain
Prior art keywords
falciparum
hepatic
epithopes
carriers
phases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92905897T
Other languages
English (en)
Inventor
Claudine Guerin-Marchand
Pierre Druilhe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Application granted granted Critical
Publication of ES2133316T3 publication Critical patent/ES2133316T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/822—Protozoa

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION CONCIERNE UNA MOLECULA O COMPOSICION POLIPEPTIDICA, CARACTERIZADA POR LA PRESENCIA EN SU ESTRUCTURA DE UNA O VARIAS SECUENCIAS PEPTIDICAS PORTADORAS DE TODO O PARTE, DE UNO O VARIOS, EPITOPE(S) T, Y SI SE PRESENTA EL CASO DE OTRO EPITOPES, EN ESPECIAL DE LOS EPITOPES B, CARACTERISTICOS DE LAS PROTEINAS QUE RESULTAN DE LA ACTIVIDAD INFECCIOSA DE P. FALCIPARUM EN LAS CELULAS HEPATICAS. CONCIERNE IGUALMENTE LA PUESTA EN OBRA DE LAS MOLECULAS EN UNOS ENSAYOS Y COFRE O KITS DE DIAGNOSTICO IN VITRO DEL PALUDISMO SOBRE UNA MUESTRA BIOLOGICA QUE PROVIENE DEL INDIVIDUO ENTRE LOS QUE LA ENFERMEDAD ESTA EN DESCUBRIR. LA INVENCION TIENE IGUALMENTE POR OBJETO LA UTILIZACION DE ESTAS MOLECULAS EN LA COMPOSICIONES DE VACUNAS CONTRA EL PALUDISMO.
ES92905897T 1991-02-05 1992-02-05 Secuencias peptidicas especificas de las fases hepaticas de p. falciparum portadoras de epitopos capaces de estimular los linfocitos t. Expired - Lifetime ES2133316T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9101286A FR2672290B1 (fr) 1991-02-05 1991-02-05 Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.

Publications (1)

Publication Number Publication Date
ES2133316T3 true ES2133316T3 (es) 1999-09-16

Family

ID=9409373

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92905897T Expired - Lifetime ES2133316T3 (es) 1991-02-05 1992-02-05 Secuencias peptidicas especificas de las fases hepaticas de p. falciparum portadoras de epitopos capaces de estimular los linfocitos t.

Country Status (10)

Country Link
US (5) US6319502B1 (es)
EP (1) EP0570489B1 (es)
AT (1) ATE179718T1 (es)
CA (3) CA2101924C (es)
DE (1) DE69229107T2 (es)
DK (1) DK0570489T3 (es)
ES (1) ES2133316T3 (es)
FR (1) FR2672290B1 (es)
GR (1) GR3030219T3 (es)
WO (1) WO1992013884A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2672290B1 (fr) 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
US20030161840A1 (en) * 1992-10-19 2003-08-28 Institut Pasteur Plasmodium falciparum antigens inducing protective antibodies
FR2735478B1 (fr) * 1995-06-13 1997-08-22 Pasteur Institut Molecules polypeptidiques de stade pre-erythrocytaire du paludisme
JP4489582B2 (ja) * 2002-05-28 2010-06-23 オムリクス・バイオフアーマシユーチカルズ・インコーポレーテツド 抗イディオタイプ抗体を得る方法
US7550275B2 (en) * 2002-11-12 2009-06-23 The United States Of America As Represented By The Secretary Of The Navy Expression, purification and uses of a Plasmodium falciparum liver stage antigen 1 polypeptide
KR101035111B1 (ko) * 2004-06-30 2011-05-19 주식회사 엘지생명과학 말라리아 플라스모듐 팔시파룸의 면역학적 측정방법 및이에 사용되는 측정 수단
KR101378872B1 (ko) 2006-09-26 2014-04-11 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 합성 애주번트를 함유하는 백신 조성물
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8262768B2 (en) 2007-09-17 2012-09-11 Barrick Gold Corporation Method to improve recovery of gold from double refractory gold ores
EA020884B1 (ru) * 2007-09-18 2015-02-27 Баррик Гольд Корпорейшн Способ восстановления золота из тугоплавких сульфидных руд
US8262770B2 (en) 2007-09-18 2012-09-11 Barrick Gold Corporation Process for controlling acid in sulfide pressure oxidation processes
SI2437753T1 (sl) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
EP2648744B1 (en) 2010-12-06 2020-06-03 MalVa GmbH Malaria vaccines based on pre-erythrocytic antigens from p. falciparum
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
KR102748354B1 (ko) 2016-06-01 2024-12-31 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU569722B2 (en) * 1983-01-28 1988-02-18 Saramane Pty Ltd Expression of plasmodium falciparum polypeptides from cloned cdna
IL76338A (en) * 1984-09-11 1994-08-26 Saramane Pty Ltd Plasmodium plasmodium immunogenic polypeptides, AND molecules encoding them, a method for preparing the polypeptides and preparations containing the polypeptide
IL78476A0 (en) * 1985-04-11 1986-08-31 Inst Medical W & E Hall Highly repetitive antigens of plasmodium falciparum
KR880701243A (ko) * 1986-03-14 1988-07-26 원본미기재 말라리아에 대한 보호 면역을 제공하는 폴리펩티드
US6270771B1 (en) * 1988-10-06 2001-08-07 Institut Pasteur Peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes
FR2610631B1 (fr) * 1987-02-09 1989-11-24 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme
FR2672290B1 (fr) * 1991-02-05 1995-04-21 Pasteur Institut Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
WO1990006130A1 (en) * 1988-11-30 1990-06-14 Biomedical Research Institute A novel malarial sporozoite and exoerythrocytic peptide antigen
FR2645877B1 (fr) * 1989-04-12 1991-07-05 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un, ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum au niveau du stade sporozoite et dans les hepatocytes
GB9020438D0 (en) * 1990-09-19 1990-10-31 Imperial College Plasmodium liver stage antigens
US6689363B1 (en) * 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
FR2697022B1 (fr) * 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
US5602831A (en) * 1995-03-31 1997-02-11 Seiko Communications Systems, Inc. Optimizing packet size to eliminate effects of reception nulls
FR2735478B1 (fr) * 1995-06-13 1997-08-22 Pasteur Institut Molecules polypeptidiques de stade pre-erythrocytaire du paludisme
JP2001509813A (ja) * 1997-01-21 2001-07-24 ニューヨーク ユニヴァーシティ 抗マラリアワクチン用ユニバーサルｔ細胞エピトープ
US6828416B1 (en) * 1998-08-21 2004-12-07 The United States Of America As Represented By The Department Of Health And Human Services Recombinant multivalent malarial vaccine against Plasmodium falciparum
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
WO2002092628A2 (fr) * 2001-05-16 2002-11-21 Institut Pasteur Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques
US20050108791A1 (en) * 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
EP2277533B1 (en) * 2002-10-23 2016-07-20 GlaxoSmithKline Biologicals S.A. Methods for vaccinating against malaria

Also Published As

Publication number Publication date
CA2638662A1 (fr) 1992-08-20
HK1014012A1 (en) 1999-09-17
CA2101924C (fr) 2005-06-28
ATE179718T1 (de) 1999-05-15
DE69229107D1 (de) 1999-06-10
US6319502B1 (en) 2001-11-20
US20060182769A1 (en) 2006-08-17
CA2101924A1 (fr) 1992-08-06
FR2672290A1 (fr) 1992-08-07
GR3030219T3 (en) 1999-08-31
EP0570489B1 (fr) 1999-05-06
WO1992013884A1 (fr) 1992-08-20
US20020041882A1 (en) 2002-04-11
CA2495581A1 (fr) 1992-08-20
US20030064075A1 (en) 2003-04-03
CA2495581C (fr) 2008-10-21
EP0570489A1 (fr) 1993-11-24
US20080213795A1 (en) 2008-09-04
US7332595B2 (en) 2008-02-19
US7087231B2 (en) 2006-08-08
US7438917B2 (en) 2008-10-21
DK0570489T3 (da) 2000-01-03
FR2672290B1 (fr) 1995-04-21
DE69229107T2 (de) 1999-12-16

Similar Documents

Publication Publication Date Title
ES2143507T3 (es) Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia.
AR005945A1 (es) Composicion farmaceutica para la modulacion inmunitaria
ES2172773T3 (es) Procedimiento de dosificado de linfocitos t especificos para un peptido.
PE20030527A1 (es) Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
HU9904549A (en) Vaccines
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
ES2117715T3 (es) Mejoras introducidas en agentes de contrastes.
BRPI0208183B8 (pt) peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
ATE331530T1 (de) Proteasom-influenzavirus-impfstoffzusammensetzu g
ES2159517T3 (es) Grapas esteriles e instrumento para su colocacion.
ES2123558T3 (es) Antigenos peptidicos del vhc y procedimiento para la determinacion del vhc.
ES2141750T3 (es) Composicion que contiene a la vez una forma soluble y una forma insoluble de un inmunogeno.
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
ES2062887T3 (es) Secuencias de adn derivadas del genoma del papilomavirus hpv39, su aplicacion al diagnostico in vitro y a la produccion de preparado inmunogeno.
AR010583A1 (es) CULTIVO DE CÉLULAS DE UNA CEPA DERIVADA DE UNA CEPA PROGENITORA DE UNA ESPECIE DE NEOSPORA, VACUNA QUE LAS CONTIENE, Y COMPOSICIoN.
CO4520254A1 (es) Vacunas contra tumores y procedimiento para su produccion
MX2025004075A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos
CA2101924A1 (fr) Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
ES2052699T3 (es) Vacuna contra la gripe.
AR071741A1 (es) Vacunas contra la malaria
ES2137160T3 (es) Lipopeptidos inductores de los linfocitos t-citotoxicos y utilizacion como vacunas.
Takemoto et al. Immunofluorescent demonstration of polyoma tumor antigen in lytic infection of mouse embryo cells
HN2002000366A (es) Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma
DE69836976D1 (de) Neospora impstoff
ES2059305T3 (es) Proteina del virus de la seudorrabia.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 570489

Country of ref document: ES